Bucladesine hemicalcium
Based on 43 publication(s) in Google Scholar
Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.58%
- CAS No.: 938448-87-4
- Formule: C18H24N5O8P·1/2Na
- Masse moléculaire:489.43
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
TGF-beta/Smad Compound Library
HY-L018
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
Nucleotide Compound Library
HY-L044
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Bucladesine hemicalcium
More- Cell Stem Cell. 2021 Aug 5;28(8):1362-1379.e7. [Abstract]
- Mol Cell. 2026 Jun 12:S1097-2765(26)00344-8. [Abstract]
- Adv Sci (Weinh). 2025 Apr 28:e2409837. [Abstract]
- Adv Sci (Weinh). 2021 Dec;8(24):e2100808. [Abstract]
- Int J Biol Sci. 2024 Aug 19;20(11):4476-4495. [Abstract]
- Cell Commun Signal. 2022 Apr 12;20(1):52. [Abstract]
- Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]
- Ecotoxicol Environ Saf. 2022 Sep 15:243:113982. [Abstract]
- J Ethnopharmacol. 2026 May 23:363:121413. [Abstract]
- Chem Biol Interact. 2025 Sep 20:111749. [Abstract]
- Cells. 2024 Jul 26;13(15):1260. [Abstract]
- Life Sci. 2025 Oct 14:382:124022. [Abstract]
- Int J Mol Sci. 2023 Feb 8;24(4):3398. [Abstract]
- Int J Mol Sci. 2023 Mar 7;24(6):5111. [Abstract]
- Int J Mol Sci. 2022 Oct 20;23(20):12595. [Abstract]
- Eur J Pharmacol. 2022 Oct 15:932:175231. [Abstract]
- Front Endocrinol. 2025 Feb 19:16:1570284. [Abstract]
- Toxicology. 2025 Jan 29:154069. [Abstract]
- Front Microbiol. 2021 Aug 17;12:692693. [Abstract]
- FASEB J. 2024 May 15;38(9):e23622. [Abstract]
- FASEB J. 2020 Oct;34(10):13376-13395. [Abstract]
- Plants. 2023 Oct 24;12(21):3666. [Abstract]
- J Neurochem. 2026 Feb;170(2):e70363. [Abstract]
- J Cell Physiol. 2025 Dec;240(12):e70118. [Abstract]
- Toxins. 2021 Aug 22;13(8):585. [Abstract]
- J Endocrinol. 2019 Sep 1;JOE-19-0284.R2. [Abstract]
- Reproduction. 2021 May 27;162(1):33-45. [Abstract]
- Mol Cell Endocrinol. 2025 May 19:112581. [Abstract]
- Genomics. 2025 Jan 21;117(2):111002. [Abstract]
- FEBS Lett. 2021 Nov;595(22):2829-2843. [Abstract]
- Cell Tissue Res. 2022 May;388(2):453-469. [Abstract]
- J Assist Reprod Genet. 2024 Jun;41(6):1669-1685. [Abstract]
- Pigment Cell Melanoma Res. 2024 Jan;37(1):21-35. [Abstract]
- J Steroid Biochem Mol Biol. 2023 Jan:225:106192. [Abstract]
- Exp Ther Med. 2022 Apr;23(4):248. [Abstract]
- Biochem Biophys Res Commun. 2025 Sep 19:785:152676. [Abstract]
- J Bone Miner Metab. 2021 Sep;39(5):748-756. [Abstract]
- Proteome Sci. 2023 Oct 11;21(1):16. [Abstract]
- bioRxiv. 2026 Jun 16.
- SSRN. 2025 Jan 27.
- Res Sq. 2024 Jun 11.
- bioRxiv. 2024 Mar 31.
- protocols.io. 2024 Jan 12.
Customer Validation & Images
-
WB
-
WB
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
Activité biologique
|
PKA |
PDE |
Bucladesine causes significant growth delay in multicellular tumor spheroids derived directly from human malignant brain tumors[1].
Bucladesine augments differentiation therapy (in combination with Sodium butyrate (HY-B0350A) and hyperthermia) in human and canine brain tumor cells in vitro[1].
Bucladesine suppresses the mitogenic effects of platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF) on human astrocytoma cells; bucladesine alone neither potentiates nor inhibits human astrocytoma cell growth[1].
Bucladesine suppresses proliferation, enhances cytoplasmic process formation, increases cytoplasmic glial fibrillary acidic protein (GFAP) levels, and suppresses malignant glioma invasion by decreasing CD44 isoform expression in cultured malignant glioma cells, inducing biochemical and morphological changes[1].
Bucladesine decreases Bcl-2 levels and enhances SNAP-induced p53-sensitive cell death and MPP+-induced cell death, sensitizing human neuroblastoma cells to apoptosis[1].
Bucladesine inhibits proliferation and induces morphological differentiation of astrocytes in vitro via a cyclic adenosine monophosphate-dependent protein kinase pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Bucladesine (50-300 nM/mouse; i.p.; single dose) exerts a biphasic anti-nociceptive effect on thermal-induced acute pain in male albino mice, with significant activity at 50 and 100 nM/mouse doses, no significant effect at 300 nM/mouse[3].
Bucladesine (0.5-1.5% cream, 5% solution; topical; single or two doses) produces a statistically significant reduction in Arachidonic acid (HY-109590)-induced acute skin inflammation in Mus musculus, with single administration of 1.5% cream yielding a 28% reduction in ear swelling and two administrations yielding a 24% reduction[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 938448-87-4
-
Appearance Solid
-
Masse moléculaire 489.43
-
Formule C18H24N5O8P·1/2Na
-
Color White to off-white
-
SMILES
O=C(CCC)O[C@H]1[C@H](N2C(N=CN=C3NC(CCC)=O)=C3N=C2)O[C@@](CO4)([H])[C@@]1([H])OP4([O-])=O.[Ca2+]
-
Synonyms
Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (43)
-
Journal Impact Factor
-
Most Recent
-
Cell Stem Cell
Organoid modeling of Zika and herpes simplex virus 1 infections reveals virus-specific responses leading to microcephaly. [Abstract]2021 Aug 5;28(8):1362-1379.e7. PMID: 33838105 -
Mol Cell
Distinct associations of pioneer factor Ascl1-E12a with nucleosomes drive changes in cell fate. [Abstract]2026 Jun 12:S1097-2765(26)00344-8. PMID: 42285106 -
Adv Sci (Weinh)
Microbiota-Derived Inosine Suppresses Systemic Autoimmunity via Restriction of B Cell Differentiation and Migration. [Abstract]2025 Apr 28:e2409837. PMID: 40289872 -
Adv Sci (Weinh)
2021 Dec;8(24):e2100808. PMID: 34719888 -
Int J Biol Sci
Chronic Stress-induced Serotonin Impairs Intestinal Epithelial Cell Mitochondrial Biogenesis via the AMPK-PGC-1α Axis. [Abstract]2024 Aug 19;20(11):4476-4495. PMID: 39247815
Bucladesine hemicalcium purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Aug 19;20(11):4476-4495. [Abstract]
The protein expression of p-AMPK (S173), p-AMPK (T172) and AMPK of HT-29 cells treated with 5-HT, either alone or in combination with H-89 (1 μM) and dbcAMP (1 μM).
-
Cell Commun Signal
Receptor activity-modifying protein 1 regulates mouse skin fibroblast proliferation via the Gαi3-PKA-CREB-YAP axis. [Abstract]2022 Apr 12;20(1):52. PMID: 35413847 -
Dev Cell
A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. [Abstract]2025 Sep 3:S1534-5807(25)00530-1. PMID: 40930100 -
Ecotoxicol Environ Saf
Fluorene-9-bisphenol regulates steroidogenic hormone synthesis in H295R cells through the AC/cAMP/PKA signaling pathway. [Abstract]2022 Sep 15:243:113982. PMID: 35987080
Bucladesine hemicalcium purchased from MedChemExpress. Usage Cited in: Ecotoxicol Environ Saf. 2022 Sep 15:243:113982. [Abstract]
H295R cells were treated with 30 μM BHPF in the absence or presence of 10 μM forskolin (FSK) or 100 μM dbcAMP for 48 h and evaluated by Western blotting.
-
J Ethnopharmacol
Targeting hypoxia: the role of ethanolic extract of Coptis chinensis Franch. in modulating HIF-1α/IL-17 axis in oropharyngeal candidiasis. [Abstract]2026 May 23:363:121413. PMID: 41747790 -
Chem Biol Interact
Phytosphingosine suppresses gastric cancer through SFRP4/β-catenin axis-mediated Wnt signaling pathway inhibition. [Abstract]2025 Sep 20:111749. PMID: 40983245 -
Cells
From Young to Old: Mimicking Neuronal Aging in Directly Converted Neurons from Young Donors. [Abstract]2024 Jul 26;13(15):1260. PMID: 39120291 -
Life Sci
Targeting Epac1 to protect the blood brain barrier from inflammation-induced dysfunction: Evidence from an in vitro model. [Abstract]2025 Oct 14:382:124022. PMID: 41101634 -
Int J Mol Sci
Galangin Rescues Alzheimer's Amyloid-β Induced Mitophagy and Brain Organoid Growth Impairment. [Abstract]2023 Feb 8;24(4):3398. PMID: 36834819 -
Int J Mol Sci
The Enzyme 15-Hydroxyprostaglandin Dehydrogenase Inhibits a Shift to the Mesenchymal Pattern of Trophoblasts and Decidual Stromal Cells Accompanied by Prostaglandin Transporter in Preeclampsia. [Abstract]2023 Mar 7;24(6):5111. PMID: 36982197 -
Int J Mol Sci
Asprosin in the Paraventricular Nucleus Induces Sympathetic Activation and Pressor Responses via cAMP-Dependent ROS Production. [Abstract]2022 Oct 20;23(20):12595. PMID: 36293450 -
Eur J Pharmacol
Pterostilbene inhibits melanogenesis, melanocyte dendricity and melanosome transport through cAMP/PKA/CREB pathway. [Abstract]2022 Oct 15:932:175231. PMID: 36038012
Bucladesine hemicalcium purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:932:175231. [Abstract]
B16F10 cells was pretreated or not with 3 μM Bucladesine sodium for 1 h before pterostilbene was applied for 24 h, 48h or 72 h at 3 μM. The CREB and p-CREB protein expression levels were detected by WB.
Bucladesine hemicalcium purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:932:175231. [Abstract]
Cell viability of H295R cells exposed to 0–40 μM BHPF in the presence of 100 μM dbcAMP for 48 h.
Bucladesine hemicalcium purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:932:175231. [Abstract]
Micrographs presenting the incorporation of EdU in H295R cells exposed to BHPF or combined with 100 μM dbcAMP for 48 h. Red: the EdU positive cells; blue: the cell nuclei (Hoechst).
-
Front Endocrinol
2025 Feb 19:16:1570284. PMID: 40046876 -
Toxicology
Cadmium induces spontaneous abortion by impairing endometrial stromal cell decidualization. [Abstract]2025 Jan 29:154069. PMID: 39892737 -
Front Microbiol
Antifungal Activity and Potential Mechanism of 6,7, 4'-O-Triacetylscutellarein Combined With Fluconazole Against Drug-Resistant C. albicans. [Abstract]2021 Aug 17;12:692693. PMID: 34484140 -
FASEB J
Long noncoding RNA BMPR1B-AS1 stability regulated by IGF2BP2 affects the decidualization in endometriosis patients through the SMAD1/5/9 pathway. [Abstract]2024 May 15;38(9):e23622. PMID: 38703029 -
FASEB J
Morinda officinalis oligosaccharides ameliorate depressive-like behaviors in poststroke rats through upregulating GLUT3 to improve synaptic activity. [Abstract]2020 Oct;34(10):13376-13395. PMID: 32812265 -
Plants
Anti-Melanogenic Effects of Lilium lancifolium Root Extract via Downregulation of PKA/CREB and MAPK/CREB Signaling Pathways in B16F10 Cells. [Abstract]2023 Oct 24;12(21):3666. PMID: 37960022 -
J Neurochem
Zinc-Mediated Lysosomal Destabilization Links Mitochondrial Damage to Neuronal Death in a Cellular MPP+ Model of Parkinson's Disease. [Abstract]2026 Feb;170(2):e70363. PMID: 41622607 -
J Cell Physiol
Telomere Attrition-Induced Senescence in Human Pluripotent Stem Cell-Derived Astrocytes: Distinct Cellular and Functional Characteristics. [Abstract]2025 Dec;240(12):e70118. PMID: 41340457 -
Toxins
2021 Aug 22;13(8):585. PMID: 34437455 -
J Endocrinol
2019 Sep 1;JOE-19-0284.R2. PMID: 31518992 -
Reproduction
2021 May 27;162(1):33-45. PMID: 34044364 -
Mol Cell Endocrinol
Embryo-derived human chorionic gonadotropin promotes human decidualization through activating epithelial prostaglandin F2α secretion. [Abstract]2025 May 19:112581. PMID: 40398806 -
Genomics
2025 Jan 21;117(2):111002. PMID: 39848478 -
FEBS Lett
miR-221/222 suppression induced by activation of the cAMP/PKA/CREB1 pathway is required for cAMP-induced bidirectional differentiation of glioma cells. [Abstract]2021 Nov;595(22):2829-2843. PMID: 34687039 -
Cell Tissue Res
MAX deficiency impairs human endometrial decidualization through down-regulating OSR2 in women with recurrent spontaneous abortion. [Abstract]2022 May;388(2):453-469. PMID: 35146559 -
J Assist Reprod Genet
2024 Jun;41(6):1669-1685. PMID: 38526774 -
Pigment Cell Melanoma Res
Modeling of pigmentation disorders associated with MITF mutation in Waardenburg syndrome revealed an impaired melanogenesis pathway in iPS-derived melanocytes. [Abstract]2024 Jan;37(1):21-35. PMID: 37559350 -
J Steroid Biochem Mol Biol
Nonclassic Adrenal Hyperplasia (NCAH) due to 21-hydroxylase deficiency: A cohort of 78 patients. [Abstract]2023 Jan:225:106192. PMID: 36167262 -
Exp Ther Med
Melatonin alleviates traumatic brain injury-induced anxiety-like behaviors in rats: Roles of the protein kinase A/cAMP-response element binding signaling pathway. [Abstract]2022 Apr;23(4):248. PMID: 35261620 -
Biochem Biophys Res Commun
Glucose transports in the ileum: mechanism, regulation and physiological role of ileal glucose absorption. [Abstract]2025 Sep 19:785:152676. PMID: 41005286 -
J Bone Miner Metab
2021 Sep;39(5):748-756. PMID: 33829324 -
Proteome Sci
Proteomic analysis of neonatal mouse hearts shows PKA functions as a cardiomyocyte replication regulator. [Abstract]2023 Oct 11;21(1):16. PMID: 37821903 -
-
-
-
-
Solvant et solubilité
H2O : 100 mg/mL (204.32 mM; Need ultrasonic)
DMSO : 100 mg/mL (204.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 110 mg/mL (224.75 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Dalbasti T, et al. Local interstitial chemotherapy with sustained release bucladesine in de novo glioblastoma multiforme: a preliminary study. J Neurooncol. 2002;56(2):167-174. [Content Brief]
[2]. Taghizadeh G, et al. Bucladesine Attenuates Spatial Learning and Hippocampal Mitochondrial Impairments Induced by 3, 4-Methylenedioxymethamphetamine (MDMA). Neurotox Res. 2020;38(1):38-49. [Content Brief]
[3]. Salehi F, et al. Effect of bucladesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain. Fundam Clin Pharmacol. 2017;31(4):411-419. [Content Brief]
[4]. Rundfeldt C, et al. The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation. Arch Dermatol Res. 2012;304(4):313-317. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.0432 mL | 10.2160 mL | 20.4319 mL | 51.0798 mL |
| 5 mM | 0.4086 mL | 2.0432 mL | 4.0864 mL | 10.2160 mL | |
| 10 mM | 0.2043 mL | 1.0216 mL | 2.0432 mL | 5.1080 mL | |
| 15 mM | 0.1362 mL | 0.6811 mL | 1.3621 mL | 3.4053 mL | |
| 20 mM | 0.1022 mL | 0.5108 mL | 1.0216 mL | 2.5540 mL | |
| 25 mM | 0.0817 mL | 0.4086 mL | 0.8173 mL | 2.0432 mL | |
| 30 mM | 0.0681 mL | 0.3405 mL | 0.6811 mL | 1.7027 mL | |
| 40 mM | 0.0511 mL | 0.2554 mL | 0.5108 mL | 1.2770 mL | |
| 50 mM | 0.0409 mL | 0.2043 mL | 0.4086 mL | 1.0216 mL | |
| 60 mM | 0.0341 mL | 0.1703 mL | 0.3405 mL | 0.8513 mL | |
| 80 mM | 0.0255 mL | 0.1277 mL | 0.2554 mL | 0.6385 mL | |
| 100 mM | 0.0204 mL | 0.1022 mL | 0.2043 mL | 0.5108 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz